Heveker N
U529 INSERM, Institut Cochin De Génétique Moléculaire, Paris, France.
Curr Drug Targets. 2001 Mar;2(1):21-39. doi: 10.2174/1389450013348849.
The discovery that chemokine receptors act as cofactors indispensable for HIV entry into target cells identified new targets for anti-retroviral therapy. However, much remains to be learned about the nature of their physiological role in the organism, as well as the molecular details of viral entry. The multitude of different receptors permitting HIV entry in vitro and their respective roles in vivo for entry, as well as their implication in distinct pathogenic events have added further complexity to this field of research. This review summarizes knowledge on HIV-coreceptors, their role under normal physiological conditions as well as in HIV pathogenesis and its implications on the development of concepts for the use of coreceptor targeting therapeutic approaches. An overview over antiviral ligands of chemokine receptors reported so far, as well as alternative strategies of antiviral interventions involving chemokine receptors is given.
趋化因子受体作为HIV进入靶细胞所必需的辅助因子这一发现,为抗逆转录病毒疗法确定了新的靶点。然而,关于它们在机体中的生理作用本质以及病毒进入的分子细节,仍有许多有待了解之处。众多不同的受体在体外允许HIV进入,它们在体内各自对于病毒进入的作用,以及它们在不同致病事件中的影响,给这一研究领域增添了更多复杂性。本综述总结了关于HIV共受体的知识,它们在正常生理条件下以及在HIV发病机制中的作用,及其对使用共受体靶向治疗方法概念发展的影响。还给出了迄今为止报道的趋化因子受体抗病毒配体的概述,以及涉及趋化因子受体的抗病毒干预替代策略。